Proteomics International Laboratories Ltd (ASX: PIQ) Share Price and News

Mr House has over 30 years of experience with multinational corporations. He previously served eight years as the Managing Director of SGS India, where he was responsible for a workforce of 4,500 personnel and 38 laboratories. Paul has previously held CFO and COO roles and has a record for delivery of business performance targets, revenue growth, margin improvement, market share and productivity, across multiple services, markets and borders.

Mr Williams is a scientist, entrepreneur, manager, director and investor with experience covering all aspects of translation technology. Over the past 25 years he has been involved from concept to commercialization, including as CEO, CTO, Director and Chair, of numerous public and private biotech companies which have resulted in five FDA approved drugs, devices and diagnostics. He conceived the technology behind iCeutica Inc (acquired in 2011). James is currently CEO of the Health Translation Group, a not-for-profit company focusing on translation of medical research outcomes, Director of the Perron Institute for Neurological and Translational Science, Director of therapeutic and agricultural start-ups Atherid Therapeutics Pty Ltd and Demagtech Pty Ltd respectively and a member of the WA State Government's Health and Medical Life Sciences Industry Advisory Group. He was previously co-founder and Investment Director of early-stage VC firm Yuuwa Capital LP, and appointed director on several portfolio companies, a Director of early-stage clinical trial facility Linear Clinical Research.

Dr Lipscombe has expertise in chemistry, immunology, mass spectrometry, peptide synthesis, high performance computing and robotics. Richard has international experience in both science and business gained over a 30-year period in Australia, USA and the UK, including work in hospital and academic laboratories and commercial organisations.

Ms Robinson brings over 20 years experience in senior executive, legal, transactional, and commercial management roles at Wesfarmers Limited, where she served on the Wesfarmers Leadership Team and as Company Secretary for Wesfarmers Limited and several subsidiaries from March 2020 to October 2023. She has non-executive director experience across diverse industries. Her current directorships include the Perron Group Limited, RACWA Holdings Pty Ltd, RAC Finance Limited, Perron Institute of Neurological and Translational Science Limited, and St Ives Group Pty Ltd.

Mr Brinkworth has a 22-year career at Gilead Sciences Inc. (Nasdaq: GILD), he held senior commercial, patient access and strategic licensing roles. Mr Brinkworth has led Gilead's Asia Pacific commercial and access operations where he was responsible for developing high performing sales, marketing, and distribution networks across the region.

Mr Morris is a global healthcare and medical technology executive with experience spanning medical devices and life sciences. His career includes executive leadership roles at Cochlear, Nanosonics, Polynovo and Monash IVF,. He brings expertise in strategy development, regulatory pathways, global market entry and market development across the Americas, Europe and Asia.

-

-

-

-

-